We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

By LabMedica International staff writers
Posted on 30 May 2024
Print article
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.

The study, conducted by researchers at Flinders University (Bedford Park, Australia), evaluated the effectiveness of on-site pathology testing, or Point-of-Care Testing (POCT), specifically for detecting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in over 100 remote Aboriginal and Torres Strait Islander communities across Australia. In these areas, point-of-care testing is crucial for reaching patients who are otherwise isolated due to geographic, social, and cultural barriers. This is particularly vital given the high rates of infectious diseases like COVID-19 among the Aboriginal and Torres Strait Islander populations, where POCT offers cost-effective, accessible, and immediate diagnostic solutions.

The study focused on the analytical quality of the Aboriginal and Torres Strait Islander COVID-19 Point-of-Care (POC) Testing Program, initiated in April 2020. This program aimed to enhance the availability of rapid, molecular-based SARS-CoV-2 detection in remote communities. Extending to 105 communities, the program effectively helped prevent a significant number of COVID-19 cases, thereby saving considerable costs for the healthcare system. The quality of COVID-19 testing within the program was supported through comprehensive operator training and the implementation of a customized External Quality Assessment (EQA) program. This EQA program was developed in collaboration with the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP).

“Our study demonstrates that when point-of-care testing models are effectively established and managed, the quality of pathology results can be equivalent to laboratory tests, and the benefits for patients are overwhelmingly evident,” said Dr Susan Matthews from the International Centre for Point-of-Care Testing at Flinders University. “The COVID-19 program has now been expanded to include testing for Influenza A and B, and respiratory syncytial virus (RSV), as well as SARS-CoV-2 and has the potential to stem acute and infectious diseases in rural and remote areas whilst saving the government billions of dollars in health costs.” The study's findings were published in the journal Diagnostics on May 26, 2024.

Related Links:
Flinders University

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.